The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Sycrest asenapine | Organon N.V. | Bipolar Disorder | 🇪🇺 EU 2010-09-01 | Order → |
| PecFent fentanyl | Gruenenthal GmbH | Pain; Cancer | 🇪🇺 EU 2010-08-31 | Order → |
| Vpriv velaglucerase alfa Accelerated assessment | Takeda Pharmaceuticals International AG Ireland Branch | Gaucher Disease | 🇪🇺 EU 2010-08-26 | Order → |
| Leflunomide medac leflunomide Generic | medac Gesellschaft für klinische Spezialpräparate mbH | Arthritis, Rheumatoid | 🇪🇺 EU 2010-07-27 | Order → |
| Ozurdex dexamethasone | AbbVie Deutschland GmbH & Co. KG | Macular Edema; Uveitis | 🇪🇺 EU 2010-07-26 | Order → |
| Daxas roflumilast | AstraZeneca AB | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2010-07-05 | Order → |
| Votrient pazopanib | Novartis Europharm Limited | Carcinoma, Renal Cell | 🇪🇺 EU 2010-06-14 | Order → |
| Olanzapine Apotex olanzapine Generic | Apotex Europe BV | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2010-06-10 | Order → |
| Ribavirin Mylan (previously Ribavirin Three Rivers) ribavirin Generic | Mylan S.A.S | Hepatitis C, Chronic | 🇪🇺 EU 2010-06-10 | Order → |
| Topotecan Hospira topotecan | Pfizer Europe MA EEIG | Uterine Cervical Neoplasms; Small Cell Lung Carcinoma | 🇪🇺 EU 2010-06-09 | Order → |
| Humenza pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted) Conditional | Sanofi Pasteur S.A. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2010-06-08 | Order → |
| Nivestim filgrastim Biosimilar | Pfizer Europe MA EEIG | Hematopoietic Stem Cell Transplantation; Cancer | 🇪🇺 EU 2010-06-07 | Order → |
| Tolura telmisartan Generic | KRKA tovarna zdravil d.d. Novo mesto | Hypertension | 🇪🇺 EU 2010-06-04 | Order → |
| Prolia denosumab | Amgen Europe B.V. | Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis | 🇪🇺 EU 2010-05-26 | Order → |
| Docefrez docetaxel Generic | Sun Pharmaceutical Industries Europe B.V. | Stomach Neoplasms; Adenoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms | 🇪🇺 EU 2010-05-10 | Order → |
| Raloxifene Teva raloxifene Generic | Teva B.V. | Osteoporosis, Postmenopausal | 🇪🇺 EU 2010-04-29 | Order → |
| Arzerra ofatumumab | Novartis Europharm Ltd | Leukemia, Lymphocytic, Chronic, B-Cell | 🇪🇺 EU 2010-04-19 | Order → |
| Ribavirin BioPartners ribavirin Generic | BioPartners GmbH | Hepatitis C, Chronic | 🇪🇺 EU 2010-04-06 | Order → |
| Arepanrix pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) Conditional | GlaxoSmithKline Biologicals S.A. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2010-03-23 | Order → |
| ImmunoGam human hepatitis B immunoglobulin | Cangene Europe Limited | Immunization, Passive; Hepatitis B | 🇪🇺 EU 2010-03-16 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.